The percentage of long‐term survivors after intensive chemotherapy and the outcome of
MDS patients who achieve partial remission (PR) with intensive chemotherapy (IC) are not …

Allogeneic hematopoietic SCT (allo-HCT) is the only curative therapy for myelodysplastic
syndrome (MDS). Numerous myeloablative (MA), nonmyeloablative SCT (NST) and reduced …

Patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) who
relapse after allogeneic hematopoietic cell transplantation (allo-HCT) generally have poor …

The efficacy of donor lymphocyte infusion (DLI) without chemotherapy was investigated and
compared with that of chemotherapy prior to DLI (Chemo-DLI) in patients who were minimal …

Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative
conditioning regimen (MAC) before allogeneic transplantation in patients with …

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem
cell neoplasms primarily affecting older persons, associated with dysplastic changes of bone …

Therapy-related myelodysplasia (MDS) is a fatal marrow disorder distinct from primary MDS.
We examined the efficacy of bone marrow transplantation (BMT) as a treatment for patients …

We report on the outcome of children with advanced primary myelodysplastic syndrome
(MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) …

Allogeneic bone marrow transplantation (BMT) is the only curative therapy available for
patients with myelodysplastic syndrome (MDS). In an attempt to identify prognostic factors …

One hundred and five consecutive primary high‐risk myelodysplastic syndromes (MDS) or
secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0–3 …